Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Strategy Could Thwart Periodontal Disease Progress

By BiotechDaily International staff writers
Posted on 02 Jan 2013
A new study suggests that blocking a specific molecular receptor on white blood cells (WBCs) could prevent periodontitis from developing, as well as halting the progression of the disease once it has already developed.

Researchers at the University of Pennsylvania (Penn, Philadelphia, USA) showed (in a mouse model) that Porphyromonas gingivalis--the bacterium responsible for many cases of periodontitis--acts by “hijacking” a receptor on WBCs called C5aR, which is part of the complement system, a component of the immune system that helps clear infection but can trigger damaging inflammation if improperly controlled. By hijacking C5aR, P. gingivalis subverts the complement system and handicaps immune cells, rendering them less able to clear infection from the gum tissue, resulting in severe inflammation.

Other studies have shown that toll-like receptors (TLRs, a set of proteins that also activate immune cell responses) may also act in concert with the complement system; in fact, mice that are C5aR-deficient and those lacking TLR2 do not develop bone loss. The researchers therefore tried to determine if the synergism seen between the complement system and TLRs was also at play in inflammatory gum disease. To find out, they injected two types of molecules, one that activated C5aR and another that activated TLR2, into the gums of mice. When only one type of molecule was administered, a moderate inflammatory response became apparent, but when injected together, inflammatory molecules increased dramatically.

In fact, the inflammatory molecules soared to levels higher than would have been expected if the effect of activating both receptors was merely additive. The finding suggested to the scientists that the TLR signaling was somehow involved in "crosstalk" with the complement system, serving to augment the inflammatory response. They then surmised that blocking one of the receptors could effectively halt the inflammation that allows P. gingivalis and other bacteria to thrive and cause disease.

To test the hypothesis, the researchers synthesized and administered a molecule that blocks the activity of C5aR to mice that were then infected with P. gingivalis. Subsequent C5aR antagonist injections were able to stave off inflammation to a large extent, reducing inflammatory molecules by 80% and completely stopping bone loss. Similar effects were seen when the mice were given the antagonist two weeks after being infected, reducing signs of inflammation by 70% and inhibiting nearly 70% of periodontal bone loss. The study was published in the Journal of Immunology.

“Regardless of whether we administered the C5a receptor antagonist before the development of the disease or after it was already in progress, our results showed that we could inhibit the disease either in a preventive or a therapeutic mode,” said senior author Professor George Hajishengallis, DDS, PhD.

Related Links:

University of Pennsylvania




Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.